Wellness and Longevity Medicine
Can the Shingles Vaccine Lower Dementia Risk? What New Studies Really Mean
New studies have linked shingles vaccination with fewer dementia diagnoses. The evidence is increasingly compelling, but the vaccine is approved to prevent shingles, not to prevent or treat dementia.

The shingles vaccine already has a clear purpose: preventing shingles and its complications. A growing series of studies now raises a fascinating second question. Could vaccination also reduce or delay dementia?
The signal is more substantial than a single headline. Researchers have reported similar findings using different vaccines, populations, and methods. One study used an unusual vaccination policy in Wales that allowed investigators to compare people born only days apart. Newer studies have examined the recombinant vaccine used in the United States today.
Still, no major medical organization recommends shingles vaccination specifically as a dementia treatment or prevention strategy. The evidence is promising, not final. Fortunately, eligible adults do not need an unproven brain-health benefit to have a sound reason for vaccination: preventing shingles remains the established goal.
First, What Is Shingles?
Shingles is caused by reactivation of varicella-zoster virus, the virus responsible for chickenpox. After chickenpox resolves, the virus remains dormant in nerve tissue. It can reactivate years later, producing a painful blistering rash, usually on one side of the body or face.
Complications can include persistent nerve pain called postherpetic neuralgia, eye disease, hearing or balance problems, and, less commonly, inflammation involving the brain or blood vessels. Risk rises with age and with conditions or treatments that weaken the immune system.
The current U.S. vaccine is Shingrix, a non-live recombinant zoster vaccine. In pooled clinical trials, it reduced shingles risk by 91.3% among adults age 70 and older. That is the proven benefit. Dementia prevention is not an FDA-approved indication.
Why Researchers Suspect a Brain Connection
Scientists are considering at least two broad explanations.
One is prevention of viral reactivation. Varicella-zoster virus can affect nerves and, in uncommon cases, cerebral blood vessels. Repeated clinical or silent reactivation might contribute to vascular injury, inflammation, or other processes relevant to cognitive decline. Preventing reactivation could therefore protect the brain indirectly.
Another possibility is broader immune modulation. Vaccines can influence immune responses beyond protection against one infection. The adjuvant in the recombinant vaccine is designed to strengthen the immune response, but whether that produces a dementia-relevant effect is unknown.
These mechanisms are biologically plausible, yet plausibility does not prove that vaccination prevents neurodegeneration. Dementia has many causes, including Alzheimer disease, vascular disease, Lewy body disease, and mixed pathology. A single immune intervention is unlikely to explain or prevent every case.
The 2025 Welsh Natural Experiment
Ordinary observational studies face a major problem called healthy-vaccinee bias. People who choose vaccination may differ from those who do not. They may have better access to care, greater health literacy, fewer barriers, or healthier behaviors. Statistical adjustment cannot capture every difference.
A 2025 Nature study used a rare policy feature to reduce this bias. When Wales introduced a live shingles vaccine, eligibility depended on an exact birthdate cutoff. People born just before September 2, 1933, were permanently ineligible, while those born just after it were eligible. Individuals separated by only days were unlikely to differ meaningfully except in their opportunity to receive the vaccine.
Vaccine uptake changed sharply at the cutoff. Over seven years, the researchers estimated that receiving the vaccine reduced the probability of a new dementia diagnosis by 3.5 percentage points, corresponding to a 20% relative reduction. The estimated effect was stronger in women.
This regression-discontinuity design is more resistant to confounding than a simple comparison of vaccinated and unvaccinated adults. It is often described as a natural experiment. It is not, however, the same as a randomized clinical trial designed in advance. The study also involved an older live vaccine, Zostavax, which is no longer available in the United States.
What Studies of the Current Vaccine Show
Evidence involving Shingrix is also encouraging.
A 2024 Nature Medicine study used the rapid U.S. transition from the older live vaccine to the newer recombinant vaccine. Receiving the recombinant vaccine was associated with 17% more time without a dementia diagnosis during six years of follow-up. Among people who later developed dementia, this translated to 164 additional diagnosis-free days. The finding was an association and the authors called for a randomized trial.
On February 9, 2026, a Nature Communications study reported results from Kaiser Permanente Southern California. It included 65,800 adults age 65 and older who completed two recombinant vaccine doses and 263,200 matched unvaccinated adults. Vaccination was associated with a 51% lower rate of dementia diagnosis.
That striking number needs context. When researchers compared shingles-vaccine recipients with people who received the Tdap vaccine, an approach intended to reduce healthy-vaccinee bias, the association became smaller but remained statistically significant. This attenuation illustrates why the 51% figure should not be interpreted as a guaranteed effect or direct proof of causation.
Natural-experiment analyses from Canada published in 2026 have added supportive evidence involving the older live vaccine. Agreement across several studies increases confidence that the signal deserves serious investigation. It does not remove the need for randomized trials, longer follow-up, validated dementia outcomes, and clarification of whether effects differ by sex or dementia type.
What This Evidence Does Not Mean
The shingles vaccine should not be presented as an Alzheimer treatment. It has not been shown to reverse memory loss, clear amyloid, slow every form of dementia, or replace a diagnostic evaluation.
It also remains uncertain whether the observed reduction reflects prevention of disease, a delay in diagnosis, protection from vascular injury, broader immune effects, residual bias, or a combination of factors. Even sophisticated observational and natural-experiment methods have limitations.
Someone with progressive memory loss, impaired judgment, language difficulty, personality change, or declining daily function should receive a clinical assessment. Vaccination is not a substitute for neurologic evaluation or for addressing established health factors such as blood pressure, diabetes, physical activity, hearing, sleep, tobacco exposure, and social connection.
Who Should Receive Shingrix?
Current CDC guidance recommends two doses of Shingrix for immunocompetent adults age 50 and older, generally separated by two to six months. It also recommends two doses for adults age 19 and older who are or will be immunodeficient or immunosuppressed. People should receive the recommended series even if they previously had shingles or received Zostavax, with timing individualized when appropriate.
If more than six months have passed since the first dose, CDC advises giving the second dose as soon as possible rather than restarting the series. Vaccination should be delayed during an active shingles episode.
Injection-site pain is common. Fatigue, muscle aches, headache, chills, fever, and gastrointestinal symptoms can occur and typically resolve within several days. A prior severe allergic reaction to a vaccine component or an earlier Shingrix dose is a contraindication. FDA labeling also notes a postmarketing signal for Guillain-Barré syndrome during the 42 days after vaccination. Individual questions should be discussed with a clinician or pharmacist.
The Practical Bottom Line
Shingrix should be offered because it is highly effective at preventing shingles and related complications in eligible adults. The possibility of reducing or delaying dementia is an important potential additional benefit, but it is not yet a promise clinicians can make.
The emerging research is scientifically meaningful because the signal appears across multiple designs and populations. The next step is confirmation through rigorous prospective studies that can determine the size, mechanism, durability, and limits of any cognitive benefit.
Brainology can help patients place vaccination within a broader, individualized plan for brain health and healthy aging. That plan should combine evidence-based prevention with careful evaluation of new research, without turning an encouraging finding into an established fact too soon.
This draft is for educational purposes and is not individualized medical advice. Vaccine decisions should be made with a qualified clinician or pharmacist who can review age, immune status, allergies, prior vaccines, and current health conditions.
References
- Centers for Disease Control and Prevention. Shingles vaccine recommendations. Updated October 22, 2024.
- U.S. Food and Drug Administration. Shingrix prescribing information. Revised February 2026.
- Eyting M, Xie M, Michalik F, et al. A natural experiment on the effect of herpes zoster vaccination on dementia. Nature. 2025;641:438-446.
- Taquet M, Dercon Q, Todd JA, Harrison PJ. The recombinant shingles vaccine is associated with lower risk of dementia. Nature Medicine. 2024;30:2777-2781.
- Rayens E, Sy LS, Qian L, et al. Recombinant zoster vaccine is associated with a reduced risk of dementia. Nature Communications. Published February 9, 2026;17:2056.
- Pomirchy M, Chung S, Bommer C, et al. Herpes zoster vaccination and incident dementia in Canada: An analysis of natural experiments. The Lancet Neurology. 2026;25(2):170-180.
- Xie M, Eyting M, Bommer C, Ahmed H, Geldsetzer P. The effect of shingles vaccination at different stages of the dementia disease course. Cell. 2025;188(25):7049-7064.e20.